What Revenue Does a Pharmacy Business Need to Attract Buyers?

Independent pharmacies typically need $4M-$8M in annual revenue to attract institutional and PE-backed buyers in 2026, with specialty, compounding, and 340B-participating pharmacies drawing interest at $2M+ because of higher margins. Retail pharmacies sell at 2.0x-4.0x SDE (0.16x-0.49x revenue), with average earnings multiples holding steady in the 2.8x-3.0x SDE range. Specialty pharmacies command premium EBITDA multiples of 6x-10x because of drug mix diversification and payor contract durability.

Retail Pharmacy Multiples: 2.0x-4.0x SDE (0.16x-0.49x revenue) | Specialty Pharmacy: 6x-10x EBITDA | Revenue to Attract PE: $4M-$8M+ retail, $2M+ specialty | Timeline: 4-12 months

What Kind of Buyer Cares About Your Revenue Size?

Different buyers have different revenue thresholds. Below $2M in revenue, your buyer pool is other independent pharmacy owners, local strategic acquirers, and sometimes wholesaler-supported successors. At $2M-$4M you start seeing regional consolidators and specialty pharmacy acquirers (if you have a niche product mix, compounding capability, or 340B contracts). At $4M-$8M, institutional buyers and PE-backed platforms become realistic. Above $10M with diversified drug mix and strong payor contracts, you're in the PE-platform sweet spot.

The revenue number alone doesn't close deals, though. Drug mix matters more than total revenue. A $3M specialty pharmacy with HIV/oncology/rare-disease dispensing and payor contracts often commands more buyer interest than a $6M retail pharmacy dispensing generics. 340B contract participation adds meaningful premium — most PE buyers specifically target pharmacies with 340B volume because the margin differential is structural. In-network contracts with major PBMs (CVS Caremark, Express Scripts, OptumRx) and MA/PDP plans are table stakes. For broader benchmarks, review the pharmacy hub page; adjacent specialties like dermatology follow the same size-drives-buyer-pool logic.

"I worked with a pharmacy owner last year at $2.8M revenue — heavy retail, thin margins, no specialty. Three buyers in the market, all independent operators, best offer was 2.6x SDE. We walked away from that deal, spent 14 months building compounding capability and adding a long-term care dispensing contract. Went back to market at $4.1M revenue with real specialty exposure. Closed at 7.8x EBITDA with a regional PE platform. Revenue scale opens doors, but drug mix opens the wallets."

— John M. Salony, Business Broker

Find Out What Your Pharmacy Business Is Worth

Start with the free valuation calculator to see where your pharmacy sits in today's market by size and drug mix. From there we can set up a confidential consultation to walk through realistic buyer options for your revenue tier.

Schedule a Confidential Consultation

Frequently Asked Questions

What Kind of Buyer Cares About Your Revenue Size?
Different buyers have different revenue thresholds. Below $2M in revenue, your buyer pool is mostly other independent pharmacy owners, local strategic acquirers, and sometimes wholesaler-supported successors. At $2M-$4M you start seeing regional consolidators and specialty pharmacy acquirers, especially if you have a niche product mix, compounding capability, or 340B contract participation. At $4M-$8M, institutional buyers and PE-backed platforms become realistic prospects. Above $10M with diversified drug mix and strong payor contracts, you're in the PE-platform sweet spot with institutional-grade buyer interest. The revenue number is a rough proxy — a $3M specialty or compounding pharmacy often attracts more buyer interest than a $6M general retail pharmacy because the margin structure and drug mix matter more than top-line.
What Drives Pharmacy Valuation Beyond Revenue?
Drug mix matters more than total revenue. Specialty dispensing (HIV, oncology, rare disease), compounding capability, long-term care dispensing contracts, and 340B contract participation all add premium. In-network contracts with major PBMs — CVS Caremark, Express Scripts, OptumRx — and participation with Medicare Advantage and Medicare Part D plans are table stakes for PE buyers. Operational factors include days' supply on hand, inventory turns, generic dispensing rate (GDR), adherence program enrollment, and MTM (medication therapy management) revenue. Regulatory hygiene — clean DEA, DOH, and PBM audit history — is critical. Pharmacies with immunization revenue, adherence packaging, and front-store retail contribution all get credit. Most importantly, pharmacies that aren't owner-operator dependent (a staff pharmacist in charge instead of the selling pharmacist-owner) attract institutional buyers who can't structure deals requiring the seller to stay long-term.